A Multicenter Comparison of Reconstruction Strategies after Wide Excision for Severe Axillary Hidradenitis Suppurativa

重度腋窝化脓性汗腺炎广泛切除术后重建策略的多中心比较

阅读:2

Abstract

An appropriate reconstruction strategy after wide excision for severe cases of axillary hidradenitis suppurativa (HS) is important to optimize outcomes, but no consensus exists on which reconstruction strategy should be preferred. OBJECTIVE: Evaluate which reconstruction strategy after wide excision in patients with severe axillary HS is associated with improved outcomes in terms of recurrence rate, complications, post-reconstruction limb function, aesthetics, and patient satisfaction. METHODS: Retrospective analysis between 2008 and 2018 of wide excision and reconstruction by primary closure (PC), secondary intention healing (SIH), split thickness skin grafts (STSG), or fasciocutaneous flaps (FCF). The primary endpoint was the rate of recurrence during follow-up. RESULTS: A total of 107 surgical interventions were performed on 54 patients. The overall recurrence rate was 31.8% after a median follow-up of 30 months, with a significant difference between PC (48%), SIH (16%), STSG (29%), and FCF (10%) (P = 0.03). Surgical complications requiring reoperation occurred in 2% after PC, 0% after SIH, 13% after STSG, and 15% after FCF (P = 0.11). The median score regarding function, aesthetics, and satisfaction after all interventions was 17 out of 20 points, but the score was lower after FCF than PC, SIH, and STSG (P = 0.03). CONCLUSIONS: Reconstruction by PC should be reserved for patients with limited HS lesions, whereas FCF was most effective in avoiding recurrence, but was associated with unfavorable short-term results and patient-reported outcomes regarding function and aesthetics. FCF should generally be reserved for patients with recurrent, severe HS comprising an extensive surface of the axillary skin.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。